

Date: 11th March 2026

To,

The National Stock Exchange of India Ltd.
The Listing Department
Exchange Plaza,
Bandra- Kurla Complex,
Mumbai - 400051
NSE Scrip Code: AHCL

To,

BSE Limited.
Department of Corporate Services
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001
BSE Scrip Code: 544497

To,

Anlon Healthcare Limited
101/102, Silvercoin Complex, Opp. Crystal Mall,
Kalawad Road, Rajkot - 360 005, Gujarat,
India.

Dear Sir/Madam,

Sub: Compliance in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

With reference to the subject matter, enclosed herewith please find Disclosure in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

You are requested to note that the said transactions

Kindly acknowledge receipt of the same.

Thanking you.

For Neomile Asset Managers Private Limited


Rashesh Shah
(Director)



Encl: a/a



NEOMILE

ASSET MANAGERS PVT. LTD.

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Anlon Healthcare Ltd		
Name(s) of the seller and Persons Acting in Concert (PAC) with the seller	Neomile Growth Fund – Series I		
Whether the seller belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited (NSE), Bombay Stock Exchanged Ltd (BSE)		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the disposal under consideration, holding of seller along with PACs of:			
a) Shares carrying voting rights	27,45,296	5.16	5.16
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	27,45,296	5.16	5.16
Details of acquisition / sale			
a) Shares carrying voting rights acquired/sold	4,07,255	0.76	0.76
b) VRs acquired /sold otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
d) Shares encumbrance/ invoked/ released by the acquirer	-	-	-
e) Total (a+b+c+-d)	4,07,255	0.76	0.76
After the acquisition/sale, holding of seller along with PACs of:			
a) Shares carrying voting rights	23,38,041	4.40	4.40
b) Shares encumbered with the seller	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after sale	-	-	-
e) Total (a+b+c+d)	23,38,041	4.40	4.40

**NEOMILE**

ASSET MANAGERS PVT. LTD.

Mode of acquisition/sale (e.g. open market /Public issue/ rights issue / preferential allotment / inter-se transfer/encumbrances, etc).	Open Market
Date of acquisition / sale of Shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Between 8th March 2026 to 10 th March 2026
Equity share capital / total voting capital of the TC before the said acquisition / sale	5,31,51,500
Equity share capital/ total voting capital of the TC after the said acquisition / sale	5,31,51,500
Total diluted share/voting capital of the TC after the said acquisition / sale	5,31,51,500

Part-B*****Name of the Target Company:** Anlon Healthcare Ltd

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and / or PACs
Neomile Growth Fund – Series I	No	AAETN3197R

For Neomile Growth Fund – Series I
CA Rashesh Shah
(Director)Place: Mumbai
Date: 11th March 2026**Note:**

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.